374 related articles for article (PubMed ID: 36795118)
1. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
Jacobs JW; Booth GS; Adkins BD
Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
[TBL] [Abstract][Full Text] [Related]
2. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
3. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune haemolytic anaemia and immune thrombocytopenia following SARS-CoV-2 and non-SARS-CoV-2 vaccination: 32 Years of passive surveillance data.
Jacobs JW; Booth GS; Guarente J; Schlafer D; Zheng L; Adkins BD
Br J Haematol; 2023 Apr; 201(2):227-233. PubMed ID: 36564040
[TBL] [Abstract][Full Text] [Related]
6. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
8. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia.
Gordon SF; Clothier HJ; Morgan H; Buttery JP; Phuong LK; Monagle P; Chunilal S; Wood EM; Tran H; Szer J; Crawford NW;
Vaccine; 2021 Nov; 39(48):7052-7057. PubMed ID: 34756770
[TBL] [Abstract][Full Text] [Related]
9. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
10. A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination.
Kim G; Choi EJ; Park HS; Lee JH; Lee JH; Lee KH
J Korean Med Sci; 2021 Nov; 36(43):e306. PubMed ID: 34751013
[TBL] [Abstract][Full Text] [Related]
11. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
12. Uncommon thrombotic complications after SARS-CoV-2 vaccination.
Musil D
Vnitr Lek; 2021; 67(5):297-302. PubMed ID: 35459396
[TBL] [Abstract][Full Text] [Related]
13. Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia.
Ruzicka M; Wurm S; Lindner L; Dreyling M; von Bergwelt-Baildon M; Boeck S; Giessen-Jung C; Milani V; Stemmler JH; Subklewe M; Weigert O; Spiekermann K
Infection; 2023 Feb; 51(1):231-238. PubMed ID: 36195695
[TBL] [Abstract][Full Text] [Related]
14. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure DL; Nelson JC; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Aug; 41(36):5265-5270. PubMed ID: 37479610
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech COVID-19 vaccine.
Aharoni M; Leader A; Shochat T; Raanani P; Spectre G
Platelets; 2022 Jul; 33(5):781-786. PubMed ID: 35536172
[TBL] [Abstract][Full Text] [Related]
16. Safety of Simultaneous Administration of Bivalent mRNA COVID-19 and Influenza Vaccines in the Vaccine Adverse Event Reporting System (VAERS).
Moro PL; Ennulat C; Brown H; Woody G; Zhang B; Marquez P; Woo EJ; Su JR
Drug Saf; 2024 May; 47(5):487-493. PubMed ID: 38411838
[TBL] [Abstract][Full Text] [Related]
17. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
Shoaibi A; Lloyd PC; Wong HL; Clarke TC; Chillarige Y; Do R; Hu M; Jiao Y; Kwist A; Lindaas A; Matuska K; McEvoy R; Ondari M; Parulekar S; Shi X; Wang J; Lu Y; Obidi J; Zhou CK; Kelman JA; Forshee RA; Anderson SA
Vaccine; 2023 Jul; 41(32):4666-4678. PubMed ID: 37344261
[TBL] [Abstract][Full Text] [Related]
19. A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine.
Malayala SV; Papudesi BN; Sharma R; Vusqa UT; Raza A
Cureus; 2021 Oct; 13(10):e18985. PubMed ID: 34820240
[TBL] [Abstract][Full Text] [Related]
20. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
